Who
Glenn Whaley
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Immunic; VP of Fin, PAO & Controller, Pernix Therapeutics Holdings.
In numbers
- Trades disclosed
- 39
- Buys
- 8
- Sells
- 0
- Bought
- $124K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 Mar 2018
- Last trade
- 29 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —280,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —560,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —560,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —280,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —280,000 at $0.00 | filing |
| 5 Jun 2025filed 20 Jun 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —503,500 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —503,000 at $0.00 | filing |
| 3 Jun 2025filed 4 Jun 2025 | IMUX ImmunicBiotechnology | SEC FORM 4 Bought | $32K45,000 at $0.71 | filing |
| 30 May 2025filed 4 Jun 2025 | IMUX ImmunicBiotechnology | SEC FORM 4 Code A | $14K25,000 at $0.56 | filing |
| 4 Dec 2024filed 6 Dec 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —265,000 at $0.00 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —70,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 | filing |
News
No headline names them, or the companies they trade most, lately.